



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

MB2002n

1990 MacArthur Blvd., Ste 300
Irvine, California 92612-2445
Telephone (949) 798-7600

WARNING LETTER

Certified Mail
Return Receipt Requested

November 17, 2000

David Sobel, M.D.
Chief Radiologist
Scripps Clinic San Diego
2020 Genesee Avenue
San Diego, CA 92123

W/L Number: 07 - 01

Inspection ID: 1356080007
CFN: 20-29,680
FEI: 1000519618

Dear Dr. Sobel:

We are writing to you because on September 29, 2000, your facility was inspected by a representative of the State of California, acting in behalf of the U. S. Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following Level 1 findings at your facility:

- Level 1: Phantom QC records were missing for the 4 weeks of July 2000 for unit #1 (a [REDACTED] machine) which is located in the Mammography Room.

The specific problem noted above appeared on your MQSA Facility Inspection Report which was issued to your facility at the close of the inspection. This problem is identified as Level 1 because it identifies a failure to meet a significant MQSA requirement.

Because this condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, it represents a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, MQSA Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

In addition, your response should address the Level 2 findings that were listed on the inspection report provided to you at the close of the inspection. These Level 2 findings are:

- Level 2: 5 of 5 random reports reviewed did not contain an assessment category.

- Level 2: Not all positive mammograms were entered in the tracking system.

Page Two of Three
November 17, 2000

re: Scripps Clinic San Diego
W/L Number: 07 - 01

- Level 2: There were no examples to obtain biopsy results nor any evidence of attempts to obtain those results.

- Level 2: The phantom image score (using an FDA approved mammography phantom) is at least 2 masses but is less than 3 masses for unit #1 (a [REDACTED] machine) which is located in the Mammography Room.

It is necessary for you to act on this matter immediately. Please explain to this office, in writing, within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations; and
- please provide sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).


Please submit your response to:

Mr. Thomas Sawyer
Director, Compliance Branch
U.S. Food & Drug Administration
19900 MacArthur Blvd.; suite #300
Irvine, CA 92612-2445
Phone: (949) 798-7600

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact [REDACTED] (MQSA Auditor) at telephone number (949) 798-[REDACTED].

Sincerely,


Alonza E. Cruse
District Director